New partnerships with Astellas, AstraZeneca, and Bristol Myers Squibb position Evinova’s AI-native platform as a shared engine for optimizing clinical development, improving efficiency, and accelerating timelines.
Evinova has entered a new phase of growth, announcing strategic collaborations with Astellas Pharma, AstraZeneca, and Bristol Myers Squibb aimed at scaling its artificial intelligence (AI)-native platform across global clinical development.1
A central component of the partnerships is an opt-in data sharing model, where participating companies contribute operational data to the platform. That aggregated dataset is then used to generate benchmarks and AI-driven recommendations intended to improve study design, execution, and overall trial performance.
The move reflects a broader industry push to address long-standing inefficiencies tied to fragmented systems and manual workflows.
“This strategic collaboration with Evinova harnesses AI to accelerate clinical development, which we believe will significantly improve productivity gains, deliver faster trials, and enhance patient experience,” said Pascal Soriot, CEO of AstraZeneca, in a company statement.
Evinova’s platform is built around multi-agent AI capabilities that support clinical development activities from protocol design through study execution. The system is designed to augment, rather than replace, human decision-making, with built-in controls to support regulatory compliance and governance.
“At Astellas, we view AI as a practical catalyst for accelerating clinical development,” said Tadaaki Taniguchi, MD, PhD, chief R&D officer at Astellas, in the statement. “By partnering with Evinova and leveraging their AI-native Study Designer platform, our teams will be able to design smarter, more patient centered studies, eliminate avoidable rework, and move with greater speed and precision as we pioneer science in breakthrough areas of R&D.”
The company reports that its technology is already delivering measurable impact, including estimated cost savings of 5% to 7% per study. Those gains are largely driven by improvements in protocol design and reductions in downstream amendments.
Several core modules underpin the platform.
“Transforming clinical development is not just an opportunity; it is an urgent necessity,” said Cristian Massacesi, MD, EVP, chief medical officer and head of development at Bristol Myers Squibb. “For years, developing medicines has taken too long, cost too much money, and mostly resulted in failure.”
Massacesi added that AI-driven tools offer a path toward more efficient development and better outcomes for patients, particularly as complexity continues to increase across therapeutic areas.
Evinova president Cristina Duran framed the collaborations as part of a broader shift toward AI-first operations.
“By uniting deep domain expertise with the power of AI, our strategic collaborations with life science leaders are moving the industry from heavy manual, fragmented processes to intelligent, AI-first workflows that deliver measurable benefits at scale,” she added.
The platform’s cloud-native architecture also allows organizations to integrate their own proprietary AI models, while maintaining data privacy and compliance across global markets.
Evinova initially announced its
The AI-enabled tool is designed to support more informed decision-making by identifying productivity opportunities and enabling more efficient study designs.
Evinova’s broader platform also incorporates agentic AI and standardized digital data flows aligned with USDM standards. According to the company, the system includes governance controls to support responsible AI use and has already been deployed at scale across multiple organizations.
Beyond protocol optimization, the platform connects various trial components—including electronic clinical outcome assessments, telehealth, and remote monitoring—into a unified digital environment.
The approach is intended to reduce operational friction for sponsors and sites while supporting more flexible trial models and improving data collection for emerging endpoints.
1. Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development. News release. Evinova. February 18, 2026. Accessed February 20, 2026.
2. Evinova, Bristol Myers Squibb Partner to Apply AI to Global Clinical Development. Applied Clinical Trials. February 10, 2026. Accessed February 20, 2026.
